Innocare Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 1,259

Employees

  • Stock Symbol
  • 09969

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.48
  • (As of Friday Closing)

Innocare General Information

Description

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Building Number 8, Number 8 Life Science Park Road
  • ZGC Life Science Park, Changping District
  • Beijing, 102206
  • China
+86 010
Primary Industry
Drug Discovery
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Building Number 8, Number 8 Life Science Park Road
  • ZGC Life Science Park, Changping District
  • Beijing, 102206
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Innocare Stock Performance

As of 13-Nov-2026, Innocare’s stock price is $1.48. Its current market cap is $3.23B with 1.77B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.48 $1.52 $1.23 - $2.07 $3.23B 1.77B 7.69M $0.08

Innocare Financials Summary

As of 30-Jun-2026, Innocare has a trailing 12-month revenue of $397M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,542,489 2,298,485 778,753 627,389
Revenue 397,368 330,246 140,681 104,389
EBITDA 143,346 98,529 (67,471) (100,192)
Net Income 131,323 89,339 (61,408) (89,226)
Total Assets 1,651,076 1,546,958 1,288,680 1,399,307
Total Debt 279,817 184,247 174,182 190,349
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Innocare Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Innocare‘s full profile, request access.

Request a free trial

Innocare Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs fo
Drug Discovery
Beijing, China
1,259 As of 2025

Suzhou, China
 

La Jolla, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Innocare Competitors (30)

One of Innocare’s 30 competitors is Alphamab Oncology, a Formerly VC-backed company based in Suzhou, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alphamab Oncology Formerly VC-backed Suzhou, China
Inhibrx Formerly VC-backed La Jolla, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
RemeGen Formerly VC-backed Yantai, China
Sutro Biopharma Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 30 competitors. Get the full list »

Innocare Patents

Innocare Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025218606-A1 Antibody fusion protein as well as preparation therefor and use thereof Pending 16-Apr-2024
US-11578058-B2 Heterocyclic compounds for inhibiting tyk2 activities Active 11-Mar-2020

Innocare Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Innocare Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Innocare‘s full profile, request access.

Request a free trial

Innocare Investments (1)

Innocare’s most recent deal was a Joint Venture with Tiannuojiancheng Pharma (InnoCare Pharma / Keymed Biosciences). The deal was made on 17-Sep-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tiannuojiancheng Pharma (InnoCare Pharma / Keymed Biosciences) 17-Sep-2021 Joint Venture Drug Discovery
To view Innocare’s complete investments history, request access »

Innocare ESG

Risk Overview

Risk Rating

Updated November, 08, 2026

32.45 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Innocare’s complete esg history, request access »

Innocare FAQs

  • When was Innocare founded?

    Innocare was founded in 2013.

  • Where is Innocare headquartered?

    Innocare is headquartered in Beijing, China.

  • What is the size of Innocare?

    Innocare has 1,259 total employees.

  • What industry is Innocare in?

    Innocare’s primary industry is Drug Discovery.

  • Is Innocare a private or public company?

    Innocare is a Public company.

  • What is Innocare’s stock symbol?

    The ticker symbol for Innocare is 09969.

  • What is the current stock price of Innocare?

    As of 13-Nov-2026 the stock price of Innocare is $1.48.

  • What is the current market cap of Innocare?

    The current market capitalization of Innocare is $3.23B.

  • What is Innocare’s current revenue?

    The trailing twelve month revenue for Innocare is $397M.

  • Who are Innocare’s competitors?

    Alphamab Oncology, Inhibrx, Inovio Pharmaceuticals, RemeGen, and Sutro Biopharma are some of the 30 competitors of Innocare.

  • What is Innocare’s annual earnings per share (EPS)?

    Innocare’s EPS for 12 months was $0.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process